PLG-related hereditary angioedema with normal C1inh

Summary

PLG-related hereditary angioedema with normal C1inh (MONDO:0035220) is a disease. A subtype of hereditary angioedema — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		105	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	PLG-related hereditary angioedema with normal C1inh
Mondo ID	MONDO:0035220
Orphanet	537072
ICD-10-CM	D84.1
UMLS	C5680155
MedGen	1843266
GARD	0022217
Is cancer (heuristic)	no

Also known as: PLG-related HAE with normal C1 inhibitor

Disease family

This is a subtype of hereditary angioedema. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › angioedema › hereditary angioedema › PLG-related hereditary angioedema with normal C1inh

Related subtypes (9): hereditary angioedema type 3, angioedema, hereditary, 6, angioedema, hereditary, 4, angioedema, hereditary, 7, angioedema, hereditary, 5, angioedema, hereditary, 8, hereditary angioedema with C1Inh deficiency, hereditary angioedema with normal C1inh not related to F12 or PLG variant, hereditary angioedema with normal C1Inh

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.